Cost-effectiveness of hypertension therapy according to 2014 guidelines

New England Journal of Medicine

Volumn 372, Issue 5, 2015, Pages 447-455

  Moran, Andrew E ^a   Odden, Michelle C ^c   Thanataveerat, Anusorn ^b   Tzong, Keane Y ^b   Rasmussen, Petra W ^b   Guzman, David ^d   Williams, Lawrence ^e   Bibbins Domingo, Kirsten ^d   Coxson, Pamela G ^d   Goldman, Lee ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Partners Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; HEALTH CARE COST; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MEDICATION COMPLIANCE; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES; AGE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION;

ANTIHYPERTENSIVE AGENT;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; SEX FACTORS;

EID: 84921845885     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa1406751     Document Type: Article

References (33)

1. US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013; 310: 591-608.
2. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009; 6(4): e1000058.
3. Cutler DM, Long G, Berndt ER, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Aff (Millwood) 2007; 26: 97-110.
4. Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA 2014; 311: 1424-9.
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
6. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.
7. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation 2014; 129: 2329-45.
8. National Health and Nutrition Survey home page (http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm).
9. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
11. Turnbull F. Effects of different bloodpressure- lowering regimens on major cardiovascular events: results of prospectively- designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
13. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
14. Average wholesale price (AWP) policy. Red Book Drug References 2014 (http://redbook.com/redbook/awp).
15. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010; 3: CD005182.
16. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA 2013; 310: 699-705.
17. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2014; 63: 878-85.
18. Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014; 160: 499-503.
19. Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older: the Framingham Heart Study. J Am Geriatr Soc 1988; 36: 1023-8.
20. Gray L, Lee IM, Sesso HD, Batty GD. Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study). J Am Coll Cardiol 2011; 58: 2396-403.
21. McCarron P, Smith GD, Okasha M, McEwen J. Blood pressure in young adulthood and mortality from cardiovascular disease. Lancet 2000; 355: 1430-1.
22. Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161: 1501-8.
23. McCarron P, Okasha M, McEwen J, Davey Smith G. Blood pressure in early life and cardiovascular disease mortality. Arch Intern Med 2002; 162: 610-1.
24. Eddy DM, Adler J, Patterson B, Lucas D, Smith KA, Morris M. Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med 2011; 154: 627-34.
25. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation 2013; 128: 2309-17.
26. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 2013; 346: f1049. abstract.
27. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003; 9: 53-61.
28. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289: 2083-93.
29. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117-24.
30. Heidenreich PA, Davis BR, Cutler JA, et al. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as firststep treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Gen Intern Med 2008; 23: 509-16.
31. Timbie JW, Hayward RA, Vijan S. Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes. Health Serv Res 2010; 45: 437-56.
32. Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. J Am Board Fam Pract 1999; 12: 105-14.
33. Sundström J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a metaanalysis of individual patient data. Lancet 2014; 384: 591-8.